Adult Dosing
Prevention of Pneumocystis carinii pneumonia
- 1500 mg (10 mL) PO once daily with food
Treatment of Mild-to-Moderate pneumocystis carinii pneumonia
- 750 mg (5 mL) PO twice daily with food x 21 days
Note: Lower plasma atovaquone concentrations and limited response to therapy may occur if administered without food
Pediatric Dosing
- Safety and efficacy in pediatric patients less than 13 yrs of age has not been established
Prevention of Pneumocystis carinii pneumonia
- 13-17 yrs: 1500 mg (10 mL) PO once daily with food
Treatment of Mild-to-Moderate pneumocystis carinii pneumonia
- 13-17 yrs: 750 mg (5 mL) PO twice daily with food x 21 days
Note: Lower plasma atovaquone concentrations and limited response to therapy may occur if administered without food
[Outline]
See Supplemental Patient Information
- Treatment of severe episodes of PCP has not been evaluated and also efficacy in patients not responding to trimethoprim-sulfamethoxazole has not been established
- Absorption of atovaquone is limited but can be significantly increased when the drug is taken with food
- Patient with GI disorder may not achieve plasma concentrations of atovaquone associated with response to therapy
- Atovaquone is not effective therapy for concurrent pulmonary conditions such as bacterial, viral, or fungal pneumonia or mycobacterial diseases. Evaluate for other possible causes of pulmonary disease in patient with acute PCP and treat with additional agents as appropriate
- Rare cases of hepatitis, elevated LFT, fatal liver failure have been reported in patients treated with atovaquone, use cautiously in patients with severe hepatic impairment
Cautions: Use cautiously in
- Severe hepatic impairment
- GI disorders
Supplemental Patient Information
- Advise patient to take the drug with food, which will significantly improve the absorption of the drug
Pregnancy Category:C
Breastfeeding: Safety unknown; quantity of drug in breast milk is assumed too low to provide adequate protection against malaria for the breastfed infant. Dosing has been established for patients weighing as little as 5 kg, so it unlikely to adversely affect breastfed infants weighing 5 kg or more. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT) last accessed 03 February 2010. Manufacturer advised caution.
Pricing data from www.DrugStore.com in U.S.A.
- Mepron 750 MG/5ML SUSP [Bottle] (GLAXO SMITH KLINE)
210 5ml = $1124.69
630 5ml = $3277.9
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
